Insektprotein ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  19.6% 10.3% 9.7% 12.6% 11.1%  
Credit score (0-100)  7 24 24 18 21  
Credit rating  B BB BB BB BB  
Credit limit (kDKK)  -0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  36 0 0 0 0  
Gross profit  -25.6 19.7 86.2 -22.6 185  
EBITDA  -29.3 19.7 86.0 -22.9 185  
EBIT  -33.8 9.6 58.9 -39.9 157  
Pre-tax profit (PTP)  -33.9 1.9 56.2 -40.2 167.2  
Net earnings  -33.9 1.9 56.2 -40.2 130.7  
Pre-tax profit without non-rec. items  -33.9 1.9 56.2 -40.2 167  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  18.3 19.0 53.0 37.6 10.0  
Shareholders equity total  -36.6 -0.3 55.8 15.6 40.0  
Interest-bearing liabilities  0.0 46.5 46.5 91.1 46.5  
Balance sheet total (assets)  36.6 46.2 157 197 280  

Net Debt  -2.1 42.0 27.7 46.9 6.5  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  36 0 0 0 0  
Net sales growth  0.0% -100.0% 0.0% 0.0% 0.0%  
Gross profit  -25.6 19.7 86.2 -22.6 185  
Gross profit growth  55.7% 0.0% 338.2% 0.0% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  37 46 157 197 280  
Balance sheet change%  47.5% 26.0% 239.6% 25.5% 42.5%  
Added value  -29.3 19.7 86.0 -12.8 185.0  
Added value %  -82.3% 0.0% 0.0% 0.0% 0.0%  
Investments  -4 -9 7 -32 -55  

Net sales trend  0.0 -1.0 0.0 0.0 0.0  
EBIT trend  -2.0 1.0 2.0 -1.0 1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  -82.3% 0.0% 0.0% 0.0% 0.0%  
EBIT %  -94.9% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  132.1% 48.7% 68.3% 176.3% 85.1%  
Net Earnings %  -95.4% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  -82.8% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  -95.4% 0.0% 0.0% 0.0% 0.0%  
ROA %  -41.4% 16.5% 57.9% -22.6% 70.2%  
ROI %  -87.7% 23.3% 79.1% -38.2% 173.3%  
ROE %  -110.3% 4.6% 110.1% -112.8% 470.9%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  -50.0% -0.8% 35.6% 7.9% 14.3%  
Relative indebtedness %  206.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  200.2% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  7.0% 213.5% 32.3% -205.1% 3.5%  
Gearing %  0.0% -13,323.8% 83.3% 585.6% 116.3%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 34.4% 5.8% 0.5% 0.2%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.2 0.3 0.7 0.7 0.9  
Current Ratio  0.5 0.6 1.9 1.2 1.4  
Cash and cash equivalent  2.1 4.5 18.8 44.2 40.0  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  64.5 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  51.5% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -16.4 -19.3 49.3 24.5 76.5  
Net working capital %  -46.2% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0